β-agonist stimulation produces changes in cardiac AMPK and coronary lumen LPL only during increased workload

American Journal of Physiology - Endocrinology and Metabolism

Volumn 288, Issue 6 51-6, 2005, Pages

  An, Ding ^a   Kewalramani, Girsh ^a   Qi, Dake ^a   Pulinilkunnil, Thomas ^a   Ghosh, Sanjoy ^a   Abrahani, Ashraf ^a   Wambolt, Rich ^a   Allard, Michael ^a   Innis, Sheila M ^a   Rodrigues, Brian ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Acetyl coenzyme A carboxylase; Adenosine 3 ,5 monophosphate activated protein kinase; Cardiomyocyte; Isoproterenol; Langendorff heart; Lipoprotein lipase; Working heart

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ADENYLATE KINASE; ALBUMIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUFFER; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; ISOPRENALINE; LIPOPROTEIN LIPASE; PALMITIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY DIAMETER; ARTICLE; BETA ADRENERGIC STIMULATION; CORONARY ARTERY; ENERGY EXPENDITURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INACTIVATION; HEART AFTERLOAD; HEART MUSCLE CELL; ISOLATED HEART; MALE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; RAT; WORKLOAD;

ACETYL-COA CARBOXYLASE; ADRENERGIC BETA-AGONISTS; ANIMALS; BLOTTING, WESTERN; ENDOTHELIUM, VASCULAR; HEART; ISOPROTERENOL; LIPOPROTEIN LIPASE; MALE; MULTIENZYME COMPLEXES; MYOCARDIAL CONTRACTION; MYOCARDIUM; MYOCYTES, CARDIAC; PHOSPHORYLATION; PHYSICAL CONDITIONING, ANIMAL; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; STIMULATION, CHEMICAL;

EID: 21144431521     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00588.2004     Document Type: Article

References (69)

1. Allard MF, Henning SL, Wambolt RB, Granleese SR, English DR, and Lopaschuk GD. Glycogen metabolism in the aerobic hypertrophied rat heart. Circulation 96: 676-682, 1997.
2. An D, Pulinilkunnil T, Qi D, Ghosh S, Abraham A, and Rodrigues B. The metabolic "switch" AMPK regulates cardiac heparin-releasable lipoprotein lipase. Am J Physiol Endocrinol Metab 288: E246-E253, 2005.
3. Atkinson LL, Fischer MA, and Lopaschuk GD. Leptin activates cardiac fatty acid oxidation independent of changes in the AMP-activated protein kinase-acetyl-CoA carboxylase-malonyl-CoA axis. J Biol Chem 277: 29424-29430, 2002.
4. Augustus AS, Kako Y, Yagyu H, and Goldberg IJ. Routes of FA delivery to cardiac muscle: modulation of lipoprotein lipolysis alters uptake of TG-derived FA. Am J Physiol Endocrinol Metab 284: E331-E339, 2003.
5. Blanchette-Mackie EJ, Masuno H, Dwyer NK, Olivecrona T, and Scow RO. Lipoprotein lipase in myocytes and capillary endothelium of heart: immunocytochemical study. Am J Physiol Endocrinol Metab 256: E818-E828, 1989.
6. Brault D, Noe L, Etienne J, Hamelin J, Raisonnier A, Souli A, Chuat JC, Dugail I, Quignard-Boulange A, Lavau M, and Galibert, F. Sequence of rat lipoprotein lipase-encoding cDNA. Gene 121: 237-246, 1992.
7. Brownsey RW, Boone AN, and Allard MF. Actions of insulin on the mammalian heart: metabolism, pathology and biochemical mechanisms. Cardiovasc Res 34: 3-24, 1997.
8. Chen ZP, Stephens TJ, Murthy S, Canny BJ, Hargreaves M, Witters LA, Kemp BE, and McConell GK. Effect of exercise intensity on skeletal muscle AMPK signaling in humans. Diabetes 52: 2205-2212, 2003.
9. Christon RA. Mechanisms of action of dietary fatty acids in regulating the activation of vascular endothelial cells during atherogenesis. Nutr Rev 61: 272-279, 2003.
10. Collins-Nakai RL, Noseworthy D, and Lopaschuk GD. Epinephrine increases ATP production in hearts by preferentially increasing glucose metabolism. Am J Physiol Heart Circ Physiol 267: H1862-H1871, 1994.
11. Coven DL, Hu X, Cong L, Bergeron R, Shulman GI, Hardie DG, and Young LH. Physiological role of AMP-activated protein kinase in the heart: graded activation during exercise. Am J Physiol Endocrinol Metab 285: E629-E636, 2003.
12. Deshaies Y, Geloen A, Paulin A, Marette A, and Bukowiecki LJ. Tissue-specific alterations in lipoprotein lipase activity in the rat after chronic infusion of isoproterenol. Horm Metab Res 25: 13-16, 1993.
13. Eckel RH. Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 320: 1060-1068, 1989.
14. Elam M, Sverrisdottir YB, Rundqvist B, McKenzie D, Wallin BG, and Macefield VG. Pathological sympathoexcitation: how is it achieved? Acta Physiol Scand 177: 405-411, 2003.
15. Enerback S and Gimble JM. Lipoprotein lipase gene expression: physiological regulators at the transcriptional and post-transcriptional level. Biochim Biophys Acta 1169: 107-125, 1993.
16. Esenabhalu VE, Cerimagic M, Malli R, Osibow K, Levak-Frank S, Frieden M, Sattler W, Kostner GM, Zechner R, and Graier WF. Tissue-specific expression of human lipoprotein lipase in the vascular system affects vascular reactivity in transgenic mice. Br J Pharmacol 135: 143-154, 2002.
17. Floras JS. Sympathetic activation in human heart failure: diverse mechanisms, therapeutic opportunities. Acta Physiol Scand 177: 391-398, 2003.
18. Goldberg DI, Rumsey WL, and Kendrick ZV. Exercise activation of myocardial lipoprotein lipase in male and estrogen-treated female rats. Metabolism 33: 964-969, 1984.
19. Goodwin GW, Ahmad F, and Taegtmeyer H. Preferential oxidation of glycogen in isolated working rat heart. J Clin Invest 97: 1409-1416, 1996.
20. Haffner SM. Lipoprotein disorders associated with type 2 diabetes mellitus and insulin resistance. Am J Cardiol 90: 55i-61i, 2002.
21. Hardie DG. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 144: 5179-5183, 2003.
22. Hardie DG and Carling D. The AMP-activated protein kinase-fuel gauge of the mammalian cell? Eur J Biochem 246: 259-273, 1997.
23. Hayashi T, Hirshman MF, Fujii N, Habinowski SA, Witters LA, and Goodyear LJ. Metabolic stress and altered glucose transport: activation of AMP-activated protein kinase as a unifying coupling mechanism. Diabetes 49: 527-531, 2000.
24. Hennig B, Shasby DM, Fulton AB, and Spector AA. Exposure to free fatty acid increases the transfer of albumin across cultured endothelial monolayers. Arteriosclerosis 4: 489-497, 1984.
25. Hong SP, Leiper FC, Woods A, Carling D, and Carlson M. Activation of yeast Snf1 and mammalian AMP-activated protein kinase by upstream kinases. Proc Natl Acad Sci USA 100: 8839-8843, 2003.
26. Horman S, Browne G, Krause U, Patel J, Vertommen D, Bertrand L, Lavoinne A, Hue L, Proud C, and Rider M. Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr Biol 12: 1419-1423, 2002.
27. Kim JK, Fillmore JJ, Chen Y, Yu C, Moore IK, Pypaert M, Lutz EP, Kako Y, Velez-Carrasco W, Goldberg IJ, Breslow JL, and Shulman GI. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci USA 98: 7522-7527, 2001.
28. Kitajima S, Morimoto M, Liu E, Koike T, Higaki Y, Taura Y, Mamba K, Itamoto K, Watanabe T, Tsutsumi K, Yamada N, and Fan J. Overexpression of lipoprotein lipase improves insulin resistance induced by a high-fat diet in transgenic rabbits. Diabetologia 47: 1202-1209, 2004.
29. Kovacic S, Soltys CL, Barr AJ, Shiojima I, Walsh K, and Dyck JR. Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J Biol. Chem 278: 39422-39427, 2003.
30. Kryski A Jr, Kenno KA, and Severson DL. Stimulation of lipolysis in rat heart myocytes by isoproterenol. Am J Physiol Heart Circ Physiol 248: H208-H216, 1985.
31. Kudo N, Barr AJ, Barr RL, Desai S, and Lopaschuk GD. High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5′-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem 270: 17513-17520, 1995.
32. Kudo N, Gillespie JG, Kung L, Witters LA, Schulz R, Clanachan AS, and Lopaschuk GD. Characterization of 5′ AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. Biochim Biophys Acta 1301: 67-75, 1996.
33. Kurth-Kraczek EJ, Hirshman MF, Goodyear LJ, and Winder WW. 5′ AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes 48: 1667-1671, 1999.
34. Levak-Frank S, Radner H, Walsh A, Stollberger R, Knipping G, Hoefler G, Sattler W, Weinstock PH, Breslow JL, and Zechner R. Muscle-specific overexpression of lipoprotein lipase causes a severe myopathy characterized by proliferation of mitochondria and peroxisomes in transgenic mice. J Clin Invest 96: 976-986, 1995.
35. Lopaschuk GD, Belke DD, Gamble J, Itoi T, and Schonekess BO. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta 1213: 263-276, 1994.
36. Luiken JJ, Coort SL, Willems J, Coumans WA, Bonen A, van der Vusse GJ, and Glatz JF. Contraction-induced fatty acid translocase/ CD36 translocation in rat cardiac myocytes is mediated through AMP-activated protein kinase signaling. Diabetes 52: 1627-1634, 2003.
37. Mardy K, Belke DD, and Severson DL. Chylomicron metabolism by the isolated perfused mouse heart. Am J Physiol Endocrinol Metab 281: E357-E364, 2001.
38. Marsin AS, Bertrand L, Rider MH, Deprez J, Beauloye C, Vincent MF, Van den Berghe G, Carling D, and Hue L. Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia. Curr Biol 10: 1247-1255, 2000.
39. Merkel M, Eckel RH, and Goldberg IJ. Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res 43: 1997-2006, 2002.
40. Mulder M, Lombardi P, Jansen H, van Berkel TJ, Frants RR, and Hayekes LM. Low density lipoprotein receptor internalizes low density and very low density lipoproteins that are bound to heparan sulfate proteoglycans via lipoprotein lipase. J Biol Chem 268: 9369-9375, 1993.
41. Otarod JK and Goldberg IJ. Lipoprotein lipase and its role in regulation of plasma lipoproteins and cardiac risk. Curr Atheroscler Rep 6: 335-342, 2004.
42. Paulson DJ and Crass MF III. Endogenous triacylglycerol metabolism in diabetic heart. Am J Physiol Heart Circ Physiol 242: H1084-H1094, 1982.
43. Pillarisetti S, Paka L, Sasaki A, Vanni-Reyes T, Yin B, Parthasarathy N, Wagner WD, and Goldberg IJ. Endothelial cell heparanase modulation of lipoprotein lipase activity. Evidence that heparan sulfate oligosaccharide is an extracellular chaperone. J Biol Chem 272: 15753-15759, 1997.
44. Pulinilkunnil T, Abrahani A, Varghese J, Chan N, Tang I, Ghosh S, Kulpa J, Allard M, Brownsey R, and Rodrigues B. Evidence for rapid "metabolic switching" through lipoprotein lipase occupation of endothelial-binding sites. J Mol Cell Cardiol 35: 1093-1103, 2003.
45. Pulinilkunnil T, An D, Yip P, Chan N, Qi D, Ghosh S, Abrahani A, and Rodrigues B. Palmitoyl lysophosphatidylcholine mediated mobilization of LPL to the coronary luminal surface requires PKC activation. J Mol Cell Cardiol 37: 931-938, 2004.
46. Pulinilkunnil T, Qi D, Ghosh S, Cheung C, Yip P, Varghese J, Abrahani A, Brownsey R, and Rodrigues B. Circulating triglyceride lipolysis facilitates lipoprotein lipase translocation from cardiomyocyte to myocardial endothelial lining. Cardiovasc Res 59: 788-797, 2003.
47. Randle PJ, Garland PB, Hales CN, and Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1: 785-789, 1963.
48. Randle PJ, Priestman DA, Mistry S, and Halsall A. Mechanisms modifying glucose oxidation in diabetes mellitus. Diabetologia 37, Suppl 1: S155-S161, 1994.
49. Robidoux J, Martin TL, and Collins S. Beta-adrenergic receptors and regulation of energy expenditure: a family affair. Annu Rev Pharmacol Toxicol 44: 297-323, 2004.
50. Rodrigues B, Cam MC, Jian K, Lim F, Sambandam N, and Shepherd G. Differential effects of streptozotocin-induced diabetes on cardiac lipoprotein lipase activity. Diabetes 46: 1346-1353, 1997.
51. Rodrigues B, Cam MC, and McNeill JH. Myocardial substrate metabolism: implications for diabetic cardiomyopathy. J Mol Cell Cardiol 27: 169-179, 1995.
52. Rodrigues B, Spooner M, and Severson DL. Free fatty acids do not release lipoprotein lipase from isolated cardiac myocytes or perfused hearts. Am J Physiol Endocrinol Metab 262: E216-E223, 1992.
53. Ruderman N and Prentki M. AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nat Rev Drug Discov 3: 340-351, 2004.
54. Ruderman NB, Saha AK, and Kraegen EW. Minireview: malonyl CoA. AMP-activated protein kinase, and adiposity. Endocrinology 144: 5166-5171, 2003.
55. Russell RR III, Bergeron R, Shulman GI, and Young LH. Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am J Physiol Heart Circ Physiol 277: H643-H649, 1999.
56. Rutledge JC and Goldberg IJ. Lipoprotein lipase (LpL) affects low density lipoprotein (LDL) flux through vascular tissue: evidence that LpL increases LDL accumulation in vascular tissue. J Lipid Res 35: 1152-1160, 1994.
57. Saddik M and Lopaschuk GD. Triacylglycerol turnover in isolated working hearts of acutely diabetic rats. Can J Physiol Pharmacol 72: 1110-1119, 1994.
58. Saha AK and Ruderman NB. Malonyl-CoA and AMP-activated protein kinase: an expanding partnership. Mol Cell Biochem 253: 65-70, 2003.
59. Schiffelers SL, van Harmelen VJ, de Grauw HA, Saris WH, and van Baak MA. Dobutamine as selective beta(1)-adrenoceptor agonist in in vivo studies on human thermogenesis and lipid utilization. J Appl Physiol 87: 977-981, 1999.
60. Severson DL, Carroll R, Kryski A Jr, and Ramirez I. Short-term incubation of cardiac myocytes with isoprenaline has no effect on heparin-releasable or cellular lipoprotein lipase activity. Biochem J 248: 289-292, 1987.
61. Steiner G. Diabetes and atherosclerosis-a lipoprotein perspective. Diabetes Med 14, Suppl 3: S38-S44, 1997.
62. Stephens TJ, Chen ZP, Canny BJ, Michell BJ, Kemp BE, and Mc-Conell GK. Progressive increase in human skeletal muscle AMPKα2 activity and ACC phosphorylation during exercise. Am J Physiol Endocrinol Metab 282: E688-E694, 2002.
63. Takahashi S, Suzuki J, Kohno M, Oida K, Tamai T, Miyabo S, Yamamoto T, and Nakai T. Enhancement of the binding of triglyceride-rich lipoproteins to the very low density lipoprotein receptor by apolipoprotein E and lipoprotein lipase. J Biol Chem 270: 15747-15754, 1995.
64. Tannock LR and Chait A. Lipoprotein-matrix interactions in macrovascular disease in diabetes. Front Biosci 9: 1728-1742, 2004.
65. Teusink B, Voshol PJ, Dahlmans VE, Rensen PC, Fiji H, Romijn JA, and Havekes LM. Contribution of fatty acids released from lipolysis of plasma triglycerides to total plasma fatty acid flux and tissue-specific fatty acid uptake. Diabetes 52: 614-620, 2003.
66. Vaziri ND, Liang K, and Barton CH. Effect of increased afterload on cardiac lipoprotein lipase and VLDL receptor expression. Biochim Biophys Acta 1436: 577-584, 1999.
67. Voshol PJ, Jong MC, Dahlmans VE, Kratky D, Levak-Frank S, Zechner R, Romijn JA, and Havekes LM. In muscle-specific lipoprotein lipase-overexpressing mice, muscle triglyceride content is increased without inhibition of insulin-stimulated whole-body and muscle-specific glucose uptake. Diabetes 50: 2585-2590, 2001.
68. Xiao RP, Zhu W, Zheng M, Chakir K, Bond R, Lakatta EG, and Cheng H. Subtype-specific beta-adrenoceptor signaling pathways in the heart and their potential clinical implications. Trends Pharmacol Sci 25: 358-365, 2004.
69. Yagyu H, Chen G, Yokoyama M, Hirata K, Augustus A, Kako Y, Seo T, Hu Y, Lutz EP, Merkel M, Bensadoun A, Homma S, and Goldberg IJ. Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest 111: 419-426, 2003.